AR096895A2 - Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) - Google Patents
Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)Info
- Publication number
- AR096895A2 AR096895A2 ARP140102580A ARP140102580A AR096895A2 AR 096895 A2 AR096895 A2 AR 096895A2 AR P140102580 A ARP140102580 A AR P140102580A AR P140102580 A ARP140102580 A AR P140102580A AR 096895 A2 AR096895 A2 AR 096895A2
- Authority
- AR
- Argentina
- Prior art keywords
- tslp
- antibody
- chain variable
- variable region
- binds
- Prior art date
Links
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000045535 human TSLP Human genes 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a compuestos de vinculación que se unen específicamente a TSLP humana, así como a sus usos, p. ej., en el tratamiento de trastornos inflamatorios. Reivindicación 1: Un compuesto de vinculación que se une específicamente a TSLP de cino y humana, que comprende: por lo menos una región variable de cadena pesada de anticuerpo, o un fragmento de vinculación a TSLP del mismo, dicha región variable de cadena pesada comprende por lo menos una secuencia de CDR seleccionada del grupo formado por las SEC ID Nº 1, 2 y 3; o por lo menos una región variable de cadena liviana de anticuerpo, o un fragmento de vinculación a TSLP del mismo, dicha región variable de cadena liviana comprende por lo menos una secuencia de CDR seleccionada del grupo formado por las SEC ID Nº 4, 5 y 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86997406P | 2006-12-14 | 2006-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096895A2 true AR096895A2 (es) | 2016-02-03 |
Family
ID=39273256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105599A AR064333A1 (es) | 2006-12-14 | 2007-12-13 | Anticuerpo anti-tslp de diseno |
| ARP140102580A AR096895A2 (es) | 2006-12-14 | 2014-07-11 | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105599A AR064333A1 (es) | 2006-12-14 | 2007-12-13 | Anticuerpo anti-tslp de diseno |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8232372B2 (es) |
| EP (2) | EP2628752A1 (es) |
| JP (2) | JP5059119B2 (es) |
| KR (1) | KR20090088950A (es) |
| CN (1) | CN101605814B (es) |
| AR (2) | AR064333A1 (es) |
| AU (1) | AU2007334499B2 (es) |
| BR (1) | BRPI0720271A2 (es) |
| CA (1) | CA2671538A1 (es) |
| MX (1) | MX2009006471A (es) |
| NO (1) | NO20092652L (es) |
| PH (2) | PH12013500356A1 (es) |
| WO (1) | WO2008076321A1 (es) |
| ZA (1) | ZA200904078B (es) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2288036T5 (es) | 1998-11-13 | 2017-07-06 | Immunex Corporation | ADN de TSLP humano y polipéptidos |
| US7288633B2 (en) | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| WO2011056772A1 (en) * | 2009-11-04 | 2011-05-12 | Schering Corporation | Engineered anti-tslp antibody |
| JP5688233B2 (ja) * | 2010-04-23 | 2015-03-25 | ポーラ化成工業株式会社 | Ｔａｒｃ産生抑制剤 |
| AU2012328952A1 (en) * | 2011-10-28 | 2014-05-01 | Merck Sharp & Dohme Corp. | IL-19 as a biomarker of TSLP treatment |
| AR090915A1 (es) * | 2012-05-04 | 2014-12-17 | Intervet Int Bv | Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg |
| US20140227250A1 (en) | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9790506B2 (en) | 2013-10-02 | 2017-10-17 | The Regents Of The University Of California | Diagnostic and screening methods for atopic dermatitis |
| JP6943568B2 (ja) * | 2013-12-06 | 2021-10-06 | アメリカ合衆国 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
| KR102496507B1 (ko) | 2014-05-07 | 2023-02-03 | 암겐 인코포레이티드 | 충격 감소 요소들을 가진 자동 주사기 |
| CA2949237C (en) | 2014-05-16 | 2022-08-23 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| KR20220143782A (ko) | 2014-06-03 | 2022-10-25 | 암겐 인코포레이티드 | 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들 |
| WO2015187519A1 (en) * | 2014-06-06 | 2015-12-10 | Merck Sharp & Dohme Corp. | Tslp assay |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
| CN114569716A (zh) | 2014-10-23 | 2022-06-03 | 美国安进公司 | 降低药物制剂的粘度 |
| US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
| CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
| WO2016142426A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
| KR101843248B1 (ko) * | 2015-03-17 | 2018-03-29 | 고려대학교 세종산학협력단 | 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물 |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| WO2017042701A1 (en) | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| EP3347377B1 (en) | 2015-09-09 | 2021-02-17 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| GB201615588D0 (en) * | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| DK3429663T3 (da) | 2016-03-15 | 2020-09-28 | Amgen Inc | Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| CN107435065B (zh) * | 2016-05-10 | 2021-06-25 | 江苏荃信生物医药有限公司 | 鉴定灵长类抗体的方法 |
| WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
| EP3582829A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Insertion mechanism for drug delivery device |
| CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
| US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
| KR102893480B1 (ko) | 2017-03-09 | 2025-11-28 | 암겐 인코포레이티드 | 약물 전달 장치용 삽입 메커니즘 |
| HUE063805T2 (hu) | 2017-03-28 | 2024-01-28 | Amgen Inc | Dugattyúrúd és fecskendõ összeállító rendszer és eljárás |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
| MA49447A (fr) | 2017-06-22 | 2020-04-29 | Amgen Inc | Réduction des impacts/chocs d'activation d'un dispositif |
| WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
| MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
| JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
| WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
| MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
| US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
| EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
| JP2021501616A (ja) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | 配置及び流量検出を備える薬物送達デバイス |
| US12053618B2 (en) | 2017-11-06 | 2024-08-06 | Amgen Inc. | Fill-finish assemblies and related methods |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| IL273638B2 (en) | 2017-11-16 | 2024-10-01 | Amgen Inc | Door latch mechanism for drug delivery device |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
| CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
| AU2019347710B2 (en) | 2018-09-24 | 2025-05-08 | Amgen Inc. | Interventional dosing systems and methods |
| IL281469B2 (en) | 2018-09-28 | 2024-08-01 | Amgen Inc | Muscle wire escapement activation assembly for a drug delivery device |
| US12156991B2 (en) | 2018-10-02 | 2024-12-03 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
| US12053617B2 (en) | 2018-10-15 | 2024-08-06 | Amgen Inc. | Drug delivery device having damping mechanism |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| US12485219B2 (en) | 2018-11-01 | 2025-12-02 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| ES3032751T3 (en) | 2019-04-24 | 2025-07-24 | Amgen Inc | Syringe sterilization verification assemblies and methods |
| TW202110882A (zh) * | 2019-06-04 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 能結合胸腺基質淋巴細胞生成素的抗體及其應用 |
| MX2022002149A (es) | 2019-08-23 | 2022-03-17 | Amgen Inc | Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados. |
| JP7331298B2 (ja) | 2019-09-04 | 2023-08-23 | ビオシオン インコーポレイテッド | 抗体結合ｔｓｌｐ及びその使用 |
| CN112876564B (zh) * | 2019-11-29 | 2022-07-15 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| MY208649A (en) | 2019-12-09 | 2025-05-22 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| KR20240011135A (ko) | 2021-05-21 | 2024-01-25 | 암젠 인크 | 약물 용기를 위한 충전 레시피를 최적화하는 방법 |
| CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN114028562B (zh) * | 2021-11-01 | 2022-05-24 | 江苏荃信生物医药股份有限公司 | 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的液体制剂 |
| WO2023070948A1 (zh) * | 2021-11-01 | 2023-05-04 | 江苏荃信生物医药股份有限公司 | 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂 |
| CN117106084B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| KR20250167153A (ko) * | 2023-03-03 | 2025-11-28 | 셀덱스 쎄라퓨틱스, 인크. | 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물 |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| WO2025077822A1 (en) * | 2023-10-12 | 2025-04-17 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-tslp antibodies and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US655520A (en) * | 1899-08-22 | 1900-08-07 | Paul Schultze | Marine velocimeter. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
| IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
| EP2314696A1 (en) | 1998-09-21 | 2011-04-27 | Schering Corporation | Therapeutic uses of human Interleukin-B50 antagonist. |
| ES2288036T5 (es) | 1998-11-13 | 2017-07-06 | Immunex Corporation | ADN de TSLP humano y polipéptidos |
| AU2396600A (en) | 1998-12-30 | 2000-07-31 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| CN1234728C (zh) * | 2001-05-16 | 2006-01-04 | 上海睿星基因技术有限公司 | 新的人淋巴因子、其编码序列及用途 |
| US7288633B2 (en) | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
| EP1487865A4 (en) * | 2002-02-01 | 2005-12-14 | Schering Corp | USE OF CYTOKIN RELATED REAGENTS OF MAMMALS |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| JP2007534307A (ja) | 2003-11-07 | 2007-11-29 | キュラジェン コーポレイション | 分泌性白血球プロテアーゼインヒビターに対する抗体 |
| AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
| AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| EP1593690B1 (en) * | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
| ATE476993T1 (de) | 2004-06-07 | 2010-08-15 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| WO2006005770A2 (en) | 2004-07-15 | 2006-01-19 | Technische Universität Wien | Method for the detection of fusarium graminearum |
| CA2577631A1 (en) | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| US20060171943A1 (en) * | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
| CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EP1891944A1 (en) | 2006-07-24 | 2008-02-27 | Association pour la recherche à l'IGBMC (ARI) | Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases |
| JP5120829B2 (ja) | 2006-10-31 | 2013-01-16 | 独立行政法人理化学研究所 | Ｔｓｌｐ遺伝子の多型に基づく免疫疾患の検査法 |
| SE532251C2 (sv) | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
-
2007
- 2007-12-13 AU AU2007334499A patent/AU2007334499B2/en not_active Ceased
- 2007-12-13 WO PCT/US2007/025531 patent/WO2008076321A1/en not_active Ceased
- 2007-12-13 EP EP13155563.3A patent/EP2628752A1/en not_active Withdrawn
- 2007-12-13 PH PH1/2013/500356A patent/PH12013500356A1/en unknown
- 2007-12-13 KR KR1020097014457A patent/KR20090088950A/ko not_active Ceased
- 2007-12-13 MX MX2009006471A patent/MX2009006471A/es active IP Right Grant
- 2007-12-13 AR ARP070105599A patent/AR064333A1/es active IP Right Grant
- 2007-12-13 US US12/515,915 patent/US8232372B2/en active Active
- 2007-12-13 PH PH1/2013/500355A patent/PH12013500355A1/en unknown
- 2007-12-13 CA CA002671538A patent/CA2671538A1/en not_active Abandoned
- 2007-12-13 JP JP2009541383A patent/JP5059119B2/ja not_active Expired - Fee Related
- 2007-12-13 EP EP07862882A patent/EP2129690A1/en not_active Withdrawn
- 2007-12-13 CN CN200780051241.7A patent/CN101605814B/zh not_active Expired - Fee Related
- 2007-12-13 BR BRPI0720271-7A2A patent/BRPI0720271A2/pt active Search and Examination
-
2009
- 2009-06-10 ZA ZA2009/04078A patent/ZA200904078B/en unknown
- 2009-07-13 NO NO20092652A patent/NO20092652L/no not_active Application Discontinuation
-
2012
- 2012-06-25 US US13/532,139 patent/US8512705B2/en active Active
- 2012-06-25 US US13/532,131 patent/US8580938B2/en active Active
- 2012-08-01 JP JP2012171162A patent/JP2013031441A/ja active Pending
-
2013
- 2013-10-08 US US14/048,636 patent/US20140141011A1/en not_active Abandoned
-
2014
- 2014-07-11 AR ARP140102580A patent/AR096895A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5059119B2 (ja) | 2012-10-24 |
| AU2007334499A1 (en) | 2008-06-26 |
| US8512705B2 (en) | 2013-08-20 |
| EP2628752A1 (en) | 2013-08-21 |
| US20130004508A1 (en) | 2013-01-03 |
| BRPI0720271A2 (pt) | 2014-01-28 |
| KR20090088950A (ko) | 2009-08-20 |
| CA2671538A1 (en) | 2008-06-26 |
| JP2010512746A (ja) | 2010-04-30 |
| US8580938B2 (en) | 2013-11-12 |
| WO2008076321A1 (en) | 2008-06-26 |
| PH12013500356A1 (en) | 2021-08-09 |
| MX2009006471A (es) | 2009-06-26 |
| EP2129690A1 (en) | 2009-12-09 |
| AR064333A1 (es) | 2009-04-01 |
| AU2007334499B2 (en) | 2014-04-24 |
| JP2013031441A (ja) | 2013-02-14 |
| US20140141011A1 (en) | 2014-05-22 |
| NO20092652L (no) | 2009-09-11 |
| US20100166766A1 (en) | 2010-07-01 |
| ZA200904078B (en) | 2010-11-24 |
| CN101605814A (zh) | 2009-12-16 |
| PH12013500355A1 (en) | 2021-08-09 |
| US8232372B2 (en) | 2012-07-31 |
| CN101605814B (zh) | 2014-02-19 |
| US20130004503A1 (en) | 2013-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
| EA200900767A1 (ru) | Антагонистические антитела против ephb3 | |
| CY1117859T1 (el) | Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης | |
| EA201070888A1 (ru) | Антитела и их производные | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| EA201170716A1 (ru) | Антитела к с-мет | |
| CO6280500A2 (es) | Anticuerpos humanizados especificos pare l factor von willebrand | |
| ATE502052T1 (de) | Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii) | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| NZ586053A (en) | Anti-vegf antibody compositions and methods | |
| AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| AR077756A1 (es) | Anticuerpos especificos para bacterias gram-positivas | |
| EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |